141 related articles for article (PubMed ID: 16630039)
1. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen.
Le Moing V; Rabaud C; Journot V; Duval X; Cuzin L; Cassuto JP; Al Kaied F; Dellamonica P; Chêne G; Raffi F;
HIV Med; 2006 May; 7(4):261-7. PubMed ID: 16630039
[TBL] [Abstract][Full Text] [Related]
2. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome.
Curran A; Falcó V; Crespo M; Martinez X; Ribera E; Villar del Saz S; Imaz A; Coma E; Ferrer A; Pahissa A
HIV Med; 2008 Oct; 9(8):609-15. PubMed ID: 18557951
[TBL] [Abstract][Full Text] [Related]
3. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
5. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
[TBL] [Abstract][Full Text] [Related]
6. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy.
Franzetti F; Grassini A; Piazza M; Degl'innocenti M; Bandera A; Gazzola L; Marchetti G; Gori A
Infection; 2006 Feb; 34(1):9-16. PubMed ID: 16501896
[TBL] [Abstract][Full Text] [Related]
7. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
8. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
Hirschtick RE; Glassroth J; Jordan MC; Wilcosky TC; Wallace JM; Kvale PA; Markowitz N; Rosen MJ; Mangura BT; Hopewell PC
N Engl J Med; 1995 Sep; 333(13):845-51. PubMed ID: 7651475
[TBL] [Abstract][Full Text] [Related]
9. Predicting bacteremic pneumonia in HIV-1-infected patients consulting the ED.
Perelló R; Miró O; Marcos MA; Almela M; Bragulat E; Sánchez M; Agustí C; Miro JM; Moreno A
Am J Emerg Med; 2010 May; 28(4):454-9. PubMed ID: 20466225
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
[TBL] [Abstract][Full Text] [Related]
11. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
14. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
Le Moing V; Chêne G; Leport C; Lewden C; Duran S; Garré M; Masquelier B; Dupon M; Raffi F;
Clin Infect Dis; 2002 Jan; 34(2):239-47. PubMed ID: 11740714
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
16. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
18. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
Sogaard OS; Lohse N; Gerstoft J; Kronborg G; Ostergaard L; Pedersen C; Pedersen G; Sørensen HT; Obel N
Clin Infect Dis; 2008 Nov; 47(10):1345-53. PubMed ID: 18834317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
